Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-12.60M | $-1.93 |
| 2024 | $1.50M | $-12.96M | $-2.35 |
| 2023 | $583.2K | $-14.29M | $-3.95 |
| 2022 | $0.00 | $-112.66M | $-1359.79 |
| 2021 | $0.00 | $-36.54M | $-34.88 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.13 per share
Typical surprise +15.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.07 vs $-0.18beat
- Wed, May 13$-0.22 vs $-0.23beat
- Mon, Mar 16$-0.32 vs $-0.38beat
- Wed, Nov 12$-0.47 vs $-0.11miss
- Tue, Aug 12$-0.53 vs $-0.77beat
- Wed, May 14$-0.66 vs $-0.65miss
Estimates and results for APRE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
APREhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·3d ago·Neutral
Aprea Therapeutics Announces Second Quarter 2026 Financial Results Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances
View source ↗